These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11255561)

  • 61. Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?
    Gold DT; Silverman SL
    Curr Osteoporos Rep; 2007 Mar; 5(1):3-7. PubMed ID: 17320021
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
    Vogel VG
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Raloxifene to prevent postmenopausal osteoporosis.
    Drug Ther Bull; 1999 May; 37(5):33-6. PubMed ID: 10563056
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Selective estrogen receptor modulators.
    Haskell SG
    South Med J; 2003 May; 96(5):469-76. PubMed ID: 12911186
    [TBL] [Abstract][Full Text] [Related]  

  • 65. How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative?
    Sismondi P; Biglia N; Roagna R; Ponzone R; Ambroggio S; Sgro L; Cozzarella M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S74-6. PubMed ID: 11056328
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women.
    Ismail SI; Bain C; Hagen S
    Cochrane Database Syst Rev; 2010 Sep; (9):CD007063. PubMed ID: 20824855
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR
    Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevention of breast cancer using SERMs.
    Powles TJ
    Adv Exp Med Biol; 2008; 630():232-6. PubMed ID: 18637495
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Review of raloxifene and its clinical applications in osteoporosis.
    Maricic M; Gluck O
    Expert Opin Pharmacother; 2002 Jun; 3(6):767-75. PubMed ID: 12036416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification of selective estrogen receptor modulators by their gene expression fingerprints.
    Zajchowski DA; Kauser K; Zhu D; Webster L; Aberle S; White FA; Liu HL; Humm R; MacRobbie J; Ponte P; Hegele-Hartung C; Knauthe R; Fritzemeier KH; Vergona R; Rubanyi GM
    J Biol Chem; 2000 May; 275(21):15885-94. PubMed ID: 10748166
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Design and methods of the Raloxifene Use for The Heart (RUTH) study.
    Mosca L; Barrett-Connor E; Wenger NK; Collins P; Grady D; Kornitzer M; Moscarelli E; Paul S; Wright TJ; Helterbrand JD; Anderson PW
    Am J Cardiol; 2001 Aug; 88(4):392-5. PubMed ID: 11545760
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Raloxifene vs tamoxifen.
    Goldstein SR
    JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
    [No Abstract]   [Full Text] [Related]  

  • 74. Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.
    McIntosh JG; Minshall J; Saya S; Bickerstaffe A; Hewabandu N; Qama A; Emery JD
    Br J Gen Pract; 2019 Dec; 69(689):e836-e842. PubMed ID: 31636127
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
    Sporn MB; Dowsett SA; Mershon J; Bryant HU
    Clin Ther; 2004 Jun; 26(6):830-40. PubMed ID: 15262454
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Selective estrogen receptor modulators (SERMs)].
    Chaki O
    Nihon Rinsho; 2015 Oct; 73(10):1673-81. PubMed ID: 26529929
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
    Riggs BL; Hartmann LC
    N Engl J Med; 2003 Feb; 348(7):618-29. PubMed ID: 12584371
    [No Abstract]   [Full Text] [Related]  

  • 78. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Selective estrogen receptor modulators (SERMs) in clinical practice.
    Plouffe L
    J Soc Gynecol Investig; 2000; 7(1 Suppl):S38-46. PubMed ID: 10732328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.